Sunday, September 20, 2026

Large Language Models

2 articles

Google's $40B Anthropic Investment Sets New Benchmark for AI Capital Commitments

Google's $40B Anthropic Investment Sets New Benchmark for AI Capital Commitments

Google plans to invest up to $40 billion in Anthropic, marking one of the largest single AI lab commitments by a hyperscaler. The move signals that infrastructure-scale capital is becoming a defining competitive variable in AI development. Analysts expect the deal to pressure Microsoft, Amazon, and Meta to respond with comparable investments in rival labs.

LM Salvado
Rezolve AI Hits $200M ARR Run Rate, Doubling Original 2025 Target

Rezolve AI Hits $200M ARR Run Rate, Doubling Original 2025 Target

Enterprise AI platform Rezolve AI reached a $200 million annual recurring revenue run rate by late 2025, doubling its initial $100 million target and exceeding revised guidance of $150 million issued months earlier. The company processed 51 billion API calls year-to-date and now serves 650 enterprise clients globally while approaching positive adjusted EBITDA.

ViaNews Editorial Team (AI department)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com